Department of Radiology , Perelman School of Medicine, University of Pennsylvania , Philadelphia , Pennsylvania 19104 , United States.
Department of Systems Pharmacology and Translational Therapeutics , University of Pennsylvania , 421 Curie Boulevard , Philadelphia , Pennsylvania 19104 , United States.
J Med Chem. 2019 May 23;62(10):5132-5147. doi: 10.1021/acs.jmedchem.9b00412. Epub 2019 May 6.
Previously, we reported a 3-(2-methoxyphenyl)-9-(3-((4-methyl-5-phenyl-4 H-1,2,4-triazol-3-yl)thio)propyl)-3,9-diazaspiro[5.5]undecane (1) compound with excellent dopamine D receptor (DR) affinity (DR K = 12.0 nM) and selectivity (DR/DR ratio = 905). Herein, we present derivatives of 1 with comparable DR affinity (32, DR K = 3.2 nM, DR/DR ratio = 60) and selectivity (30, DR K = 21.0 nM, DR/DR ratio = 934). Fragmentation of 1 revealed orthosteric fragment 5a to express an unusually low DR affinity ( K = 2.7 μM). Compared to piperazine congener 31, which retains a high-affinity orthosteric fragment (5d, DR K = 23.9 nM), 1 was found to be more selective for the DR among D- and D-like receptors and exhibited negligible off-target interactions at serotoninergic and adrenergic G-protein-coupled receptors (GPCRs), common off-target sites for piperazine-containing DR scaffolds. This study provides a unique rationale for implementing weakly potent orthosteric fragments into DR ligand systems to minimize drug promiscuity at other aminergic GPCR sites.
此前,我们报道了一种 3-(2-甲氧基苯基)-9-(3-((4-甲基-5-苯基-4H-1,2,4-三唑-3-基)硫代)丙基)-3,9-二氮杂螺[5.5]十一烷(1)化合物,具有优异的多巴胺 D 受体(DR)亲和力(DR K = 12.0 nM)和选择性(DR/DR 比值 = 905)。在此,我们呈现了 1 的衍生物,它们具有可比的 DR 亲和力(32,DR K = 3.2 nM,DR/DR 比值 = 60)和选择性(30,DR K = 21.0 nM,DR/DR 比值 = 934)。1 的片段化揭示了正位片段 5a 表达出异常低的 DR 亲和力(K = 2.7 μM)。与保留高亲和力正位片段的哌嗪同系物 31 相比(5d,DR K = 23.9 nM),1 被发现对 DR 具有更高的选择性,并且在血清素能和肾上腺素能 G 蛋白偶联受体(GPCR)中表现出可忽略不计的脱靶相互作用,这些受体是哌嗪类 DR 支架的常见脱靶位点。这项研究为在 DR 配体系统中引入弱效正位片段提供了一个独特的原理,以最小化其他单胺能 GPCR 位点的药物混杂性。